CEVEC Pharma
Gottfried-Hagen-Str. 62
Köln
D-51105
Germany
Tel: 49-22-46020800
Fax: 49-22-46020801
29 articles about CEVEC Pharma
-
Cytiva strengthens cell line development with CEVEC acquisition
10/6/2022
Global life sciences leader Cytiva has acquired CEVEC Pharmaceuticals, a leading German provider of high-performance cell line development and viral vector manufacturing technologies.
-
CEVEC Pharmaceuticals GmbH: ROKOTE Laboratories Licenses CEVEC's CAP(R) Ad Technology for Vaccine Manufacturing
9/20/2022
CEVEC Pharmaceuticals GmbH (CEVEC) and ROKOTE Laboratories Finland Ltd today announced the signing of an agreement on the use of CEVEC's proprietary CAP® Ad Technology for the manufacturing of vaccines in various indications.
-
CEVEC's License Partner RZNOMICS Inc. Receives Approval to Initiate Clinical Development of CAP(R) Ad Technology-Produced Gene Therapy Vector in Liver Cancer Patients
7/13/2022
South Korean Ministry of Food and Drug Safety granted IND approval for a clinical phase 1/2a trial to evaluate safety and efficacy of RZNOMICS lead gene therapy RZ001 for the treatment of primary liver cancer.
-
CEVEC Pharmaceuticals GmbH: CEVEC Closes Growth Financing Round to Serve Strong Demand in Viral Vector Technologies for Cell and Gene Therapies
7/27/2021
CEVEC Pharmaceuticals GmbH, the leading provider of high-performance cell technology for scalable manufacturing of advanced bio-therapeutics, announced the successful closing of an internal growth financing round.
-
Biogen reported that its gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
-
CEVEC and CARISMA Therapeutics Sign License Agreement for the Use of CAP(R) Technology in Anti-Tumor Cell Therapies
2/2/2021
CARISMA receives full rights to use the CAP(R) Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications CEVECs unique CAP(R) cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors
-
CEVEC Signs Agreement with Roche for the Use of CEVEC's ELEVECTA(R) Technology in Gene Therapy
11/10/2020
CEVEC Pharma GmbH (CEVEC) today announced the signing of an option and license agreement with Roche for the use of its newly launched ELEVECTA(R) Technology for large scale manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.
-
CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use
4/16/2020
CEVEC Pharmaceuticals GmbH announced the signing of a license agreement with Evox Therapeutics, Ltd. for the development and commercialization of therapeutic exosomes using CEVEC’s proprietary CAP® technology.
-
CEVEC and CellGenix announce the launch of GMP-grade TGF-ß1 for cell and gene therapy applications
12/19/2019
CEVEC’s CAP®Go technology enables CellGenix to offer rh TGF-ß1 in preclinical and now also in GMP-grade quality, allowing a seamless transition from preclinical to clinical development and commercial manufacturing of cell therapy products
-
CEVEC closes major financing round to further expand and commercialize its viral vector manufacturing platform
4/16/2019
CEVEC Pharmaceuticals GmbH announced the successful closing of a Series D financing round with new and existing investors.
-
CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC's proprietary CAP(R)Go technology
5/8/2018
CEVEC Pharmaceuticals GmbH announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC's proprietary CAP(R)Go technology.
-
CEVEC Has Been Granted a New CAPGo Technology Patent And Reinforces its Leading Role in Production of Recombinant Proteins Previously Out of Reach
11/14/2017
The patent broadly protects genetically engineered cell lines for the production of O-glycosylated proteins with a significantly improved plasma half-life.
-
CEVEC Pharma Intensifies Its Marketing Activities, Presenting At Various Renowned Scientific Conferences In Europe And The U.S.
2/22/2016
-
CEVEC Pharma And Genethonn Sign A Collaboration Agreement To Develop Lentiviral Vector Packaging Cell Lines Based On CEVEC's Proprietary CAP(R)GT Technology
9/17/2015
-
CEVEC Pharma's CAP(R)Go Derived Recombinant Placental Human Alkaline Phosphatase Shows Superior Results In A Preclinical Study
7/6/2015
-
CEVEC Pharma Grants License To Biotest AG For Production Of Tailor-Made Glycoproteins
7/1/2015
-
CEVEC Pharma Introduces CAP Go Expression System For Scalable Production Of Tailor-Made Glycoproteins
6/1/2015
-
CEVEC Pharma Introduces CMO Services For The cGMP Manufacturing Of CAP Based Clinical Materials
9/23/2014
-
CEVEC Pharma Release: Completion of a "First in Human" Clinical Phase I Study With a Therapeutic Protein Derived From CAP® Cells
11/1/2013
-
CEVEC Pharma and Vakzine Projekt Management Sign Exclusive License Agreement on the Clinical Development of a Novel Human Cytomegalovirus (CMV) Vaccine
1/3/2013